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926 The Journal of Thoracic and CardioObjective: Multiple gene transfer might permit modulation of concurrent biochem-
ical pathways involved in acute lung graft rejection. We investigated whether gene
cotransfection into the recipient reduces acute lung graft rejection.
Methods: Brown Norway rats were used as donors, and F344 rats were used as
recipients. Recipient animals were injected with saline (groups I/VI) or 1 1010 pfu
of adenovirus encoding -galactosidase (groups II/VII), transforming growth factor
1 (groups III/VIII), interleukin 10 (groups IV/IX), or both transforming growth
factor 1 and interleukin 10 (groups V/X) into both leg muscles 2 days before
transplantation (groups I-V) or at the time of harvest (groups VI-X). The Kruskal-
Wallis test for rejection score and 1-way analysis of variance were used to compare
groups.
Results: Oxygenation was significantly improved in the cotransfected groups treated
2 days before transplantation and at the time of harvest. Rejection scores were also
reduced in the cotransfected groups. In group V cotransfection suppressed endog-
enous interleukin 2 but not interferon  and tumor necrosis factor .
Conclusion: Recipient intramuscular cotransfection of transforming growth factor
1 and interleukin 10 suppressed interleukin 2 expression and provided a synergistic
effect that reduced acute lung graft rejection. This approach might be applied to the
clinical setting because transplant recipients could be treated at the time of implan-
tation.
Although lung transplantation has proved to be a therapeutic optionfor a variety of end-stage pulmonary diseases, acute and chronicrejection continue to affect lung transplantation. Donor lung genetransfer has tremendous potential for the treatment of pulmonarydisease by providing local immunosupression.1,2 Gene transferinto the recipient is another potential therapeutic option. Recipient
intramuscular gene transfection of major histocompatibility complex class I antigen
and transforming growth factor 1 (TGF-1) decreases experimental graft rejec-
tion.3,4 These studies suggest that the transgene products enter into the recipient’s
circulation, resulting in beneficial effects on the transplanted organs.
TGF-1 is one of a number of closely related and multifunctional molecules that
play a central role in embryonic development, tumorigenesis, wound healing,
fibrosis, and immunoregulation.4,5 The immunomodulator function occurs by sup-
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inflammatory cytokines, such as interleukin 2 (IL-2), tumor
necrosis factor  (TNF-), and interferon  (IFN-); and by
inhibiting natural killer cells.5-7 In experimental models
expression of TGF-1 has been clearly implicated in the
establishment of tolerance.8 IL-10 is produced by TH2 cells
and macrophages and plays an immunosuppressive role by
decreasing both the expression of proinflammatory cyto-
kines and the expression of class II major histocompatibility
complex antigens and antigen-presenting cell function.9
Multiple gene transfer of these cytokines might provide
synergistic benefits and might permit modulation of concur-
rent biochemical pathways involved in acute lung graft
rejection.
We hypothesized that intramuscular TGF-1 and IL-10
gene cotransfection into the recipient would inhibit the
immune response and suppress acute allograft rejection.
The aim of the present study was to investigate the feasi-
bility of gene cotransfection with TGF-1 and IL-10 into
the recipient by using an adenoviral vector to study its
synergistic effects on acute rejection in a lung transplant
model.
Materials and Methods
The aim of the first study (nontransplant setting, experiment 1) was
to demonstrate the feasibility of in vivo gene delivery in muscle.
The second study (experiment 2) was conducted to evaluate the
effect of TGF-1 and IL-10 gene cotransfection into the recipient
in a rat lung transplant model of acute rejection and to measure
endogenous cytokine expression in the grafts.
Animals
F344 rats and Brown Norway rats (Harlan Sprague Dawley Inc,
Indianapolis, Ind) weighing 250 to 270 g were used in all exper-
iments. All animal procedures were approved by the Animal
Studies Committee at Washington University. Animals received
humane care in compliance with “Principles of Laboratory Animal
Care” formulated by the National Society for Medical Research
and the “Guide for the Care and Use of Laboratory Animals”
prepared by the National Academy of Sciences and published by
the National Institutes of Health (National Institutes of Health
publication no. 85-23, revised 1996).
Adenoviral Vectors
Adenovirus encoding rat TGF-1 (AdCMVTGF1; provided by
Dr Debra A. Hullett, Department of Surgery, University of
Wisconsin, Madison, Wis) is a replication-deficient adenoviral
vector encoding the mutated bioactive TGFB1 gene driven by the
cytomegalovirus immediate early promoter. This contains a muta-
tion of cysteine to serine at positions 223 and 225, rendering the
expressed TGF-1 biologically active.4
Adenovirus encoding human IL-10 (AdRSIL-10; purchased
from Gene Therapy Vector Core at the University of Iowa School
of Medicine, Iowa) is a replication-deficient adenoviral vector
encoding the human IL-10 gene and driven by the rous sarcoma
virus (RSV) promoter.
The Journal of ThoraciFirst-generation replication-deficient adenovirus serotype 5
carrying the Escherichia coli LacZ gene encoding for -galacto-
sidase (gal) and driven by the constitutive cytomegalovirus pro-
moter (AdCMVgal) served as a control adenoviral vector. It was
provided as a gift from the Gene Therapy Center at the University
of North Carolina, Chapel Hill.
Adenoviral amplification was achieved by means of propaga-
tion in 293 cells to obtain high-titer stocks, as determined by using
the plaque assay (courtesy of Dr R. Jude Samulski and Dr Douglas
McCarty, Gene Therapy Center Vector Core Facility, University
of North Carolina, Chapel Hill, NC). Purified viral aliquots were
stored at 80°C in 10% glycerol buffered with 10 mmol/L Tris,
140 mmol/L NaCl, and 1 mmol/L MgCl2. Immediately before use,
these stocks were thawed and diluted in 1 mL of sterile normal
saline.
Experimental Groups
The expression of TGF-1 and IL-10 in muscle has been
demonstrated in our previous studies.4,10
Effects of Active TGF-1 and IL-10 Gene
Transfection (Groups I-X)
Animals were randomly divided into 10 groups (n  5 per
group). Brown Norway rats (RT1n) served as donors, and
F344 rats (RT11v1) served as recipients. This strain com-
bination was chosen because of the strong major and minor
histocompatibility locus mismatch that results in well-doc-
umented complete lung graft rejection within the fifth post-
operative day in control animals without immunosuppres-
sion. Recipient animals received 1 1010 pfu of adenovirus
encoding active TGF-1 (groups I and VI), IL-10 (groups II
and VII), both TGF-1 and IL-10 (groups III and VIII),
gal as an adenoviral control (groups IV and IX), or normal
saline without adenovirus (groups V and X) 2 days before
transplantation (groups I-V) or at the time of harvest
(groups VI-X). Donor lungs were harvested as described
below. Briefly, after achievement of general anesthesia,
mechanical ventilation, and systemic heparinization, donor
rat lungs were flushed through the main pulmonary artery
with 20 mL of cold (4°C) low-potassium dextran–1% glu-
cose solution at 20 cm H2O pressure. The heart-lung bloc
was removed with the lungs inflated at end-tidal volume.
The left lung was stored at 4°C in low-potassium dex-
tran–1% glucose until implantation. Recipient animals were
anesthetized and intubated and underwent a left thoracot-
omy. The pulmonary vessels were anastomosed by a mod-
ification of the previously described cuff technique.11 The
bronchial anastomosis was performed by a running 8-0
Prolene suture (Ethicon, Inc, Somerville, NJ). Ventilation
and perfusion were restored, and a temporary chest tube was
placed, which was removed after recovery from anesthesia.
In all groups no immunosuppressive drugs were used, and
recipients were put to death on the fifth postoperative day.4
Recipient animals were reanesthetized with the donor tech-
c and Cardiovascular Surgery ● Volume 129, Number 4 927
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nique described above and mechanically ventilated with
100% oxygen. Median laparotomy-sternotomy was per-
formed, and the contralateral right hilum was clamped.
Animals’lungs were then ventilated for 5 minutes with a
tidal volume of 1.5 mL, a respiratory rate of 100 breaths/
min, and a peak end-expiratory pressure of 1.0 cm H2O to
assess the function of the isolated left lung graft by means
of arterial blood gas analysis with blood samples obtained
from the ascending aorta. After the animals were put to
death, the lung graft was flushed with cold saline solution,
and the grafts were subjected to enzyme-linked immunosor-
bent assay (ELISA) testing to investigate the endogenous
Figure 1. Mean Pao2 after monoventilation of the allog
values in groups III, IV, and V were superior in compari
superior in comparison with those in groups VI, VII, V
TABLE 1. Histologic rejection score 5 days after transplan-
tation
Groups
Histologic rejection score
(vascular/airway)
I (saline) 3.3 0.1/2.8 0.2
II (-galactosidase) 3.1 0.1/2.7 0.2
III (TGF-1) 2.6 0.1/2.2 0.1
IV (IL-10) 2.7 0.2/ 2.3 0.2
V (TGF-1  IL-10) 2.5 0.1*/2.0 0.2
VI (saline) 3.3 0.2/3.0 0
VII (-galactosidase) 3.2 0.1/2.9 0.1
VIII (TGF-1) 2.5 0.1/2.4 0.2
IX (IL-10) 2.6 0.8/2.5 0.2
X (TGF-1  IL-10) 2.3 0.1*/2.3 0.2
TGF, Transforming growth factor; IL, interleukin.cytokine expression in the transplanted lungs.
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Lungs were perfused through the pulmonary arterial trunk
with 20 mL of normal saline and 20 mL of Histochoice
(Amresco, Solon, Ohio). The specimens were fixed in His-
tochoice for 24 hours at 4°C and embedded in paraffin wax.
Tissue sections 7-m thick were cut on a microtome and
mounted on slides. Lungs were stained with hematoxylin
and eosin. A blinded observer (pathologist, J.H.R.) scored
rejection according to the 1995 revision of the working
formulation for the classification of pulmonary allograft
rejection.12 Vascular and airway rejection scores ranged
from 0 (no rejection) to 4 (complete destruction of the
allograft).
ELISA for Cytokines
Levels of the cytokines IL-10, TGF-1, IL-2, TNF-, and
IFN- in experimental lung grafts were measured for each
group by using ELISA-based techniques. Protein extraction
was performed by homogenizing lung grafts in lysis solu-
tion containing 100 mmol/L potassium phosphate (pH 7.8),
0.2% triton X-100 with pepstatin A (5 g/mL), and protease
inhibitor cocktail (Complete Mini tabs, Boehringer-
Mannheim). The homogenate was then centrifuged at
15,000 rpm for 15 minutes after extraction at room temper-
ature for 15 minutes, and the supernatant was stored at
80°C until ELISA assessment. Human IL-10, human
TGF-1, rat IL-2, rat TNF-, and rat IFN- Quantikine
ELISA kits (R&D Systems, Minneapolis, Minn) were used
in this study. The human TGF-1 and IL-10 ELISA kits are
t the time of death on the fifth postoperative day. PaO2
ith those in groups I and II (A). Values in group X was
nd IX (B). *P < .05.raft a
son wcross-reactive for human, rat, and mouse. The procedure to
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the detection of active TGF-1.
Statistical Analysis
Values are reported as means  SEM. For the pathologic
rejection score, the Kruskal-Wallis rank test was used to
compare groups. For other assessments, 1-way analysis of
variance with pairwise comparison by the Fisher protected
least significant difference method was used to compare
overall differences among groups.
Results
Groups I-V Transfected 2 Days Before
Transplantation
Left lungs from groups III, IV, and V, which had been
transfected with TGF-1, IL-10, and both TGF-1 and
IL-10, respectively, had superior PaO2 levels compared with
control groups I or II (Figure 1, A). Mean PaCO2 levels were
not significantly different in any of the groups (32.98 
5.44, 31.58  5.7, 22.78  2.4, 22.9  3.2, and 25.53 
4.41 mm Hg for groups I, II, III, IV, and V, respectively,
P  .5).
Vascular rejection scores and airway rejection scores of
the contransfection group (group V) were significantly
lower compared with those of the other groups (Table 1).
Endogenous IL-2 levels were lower in group V com-
pared with those in groups I or II (Figure 2). Endogenous
TNF- levels were not significantly different in any of the
groups (10.1  1.62, 11.0  1.16, 10.06  0.56, 8.58 
1.62, and 10.37  1.14 pg/mg total protein for groups I, II,
III, IV, and V, respectively; P  .5). Similarly, endogenous
Figure 2. Endogenous IL-2 expression in the groups tra
lower in group V compared with that in the control grIFN- levels were not significantly different in any of the
The Journal of Thoracigroups (241.34  25.95, 214.95  28.55, 180.59  23.59,
185.94  21.52, and 245.39  35.4 pg/mg total protein for
groups I, II, III, IV, and V, respectively; P  .5).
Groups VI-X Transfected at the Time of Harvest
Left lungs from group X, which had been cotransfected with
both TGF-1 and IL-10, had superior PaO2 levels compared
with those of the other groups (Figure 1, B). Mean PaCO2
levels were not significantly different in any of the groups
(37.19  5.05, 32.98  3.95, 32.47  4.68, 25.25  2.75,
and 26.47  4.15 mm Hg for groups VI, VII, VIII, IX, and
X, respectively; P  .5). Vascular rejection scores and
airway rejection scores of group X were significantly lower
compared with those of the other groups (Table 1).
Endogenous IL-2 levels were not significantly different
in any of the groups (17.15  1.74, 16.75  2.18, 12.91 
3.08, 11.08  6.0, and 12.3  5.95 pg/mg total protein for
groups VI, VII, VIII, IX, and X, respectively;
P  .5). Similarly, endogenous TNF- levels were not
significantly different in any of the groups (9.83  0.92,
10.96 1.17, 14.48 3.18, 9.47 0.94, and 11.16 1.27
pg/mg total protein for groups VI, VII, VIII, IX, and X,
respectively; P  .5). Endogenous IFN- levels were not
significantly different in any of the groups (201.66 21.98,
199.59  30.48, 184.31  18.98, 204.22  49.66, and
229.78 17.78 pg/mg total protein for groups VI, VII, VIII,
IX, and X, respectively; P  .5).
Discussion
In the present study we demonstrated that recipient intra-
ted 2 days before transplantation. IL-2 expression was
.nsfecmuscular cotransfection of TGF-1 and IL-10 suppressed
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duced acute lung graft rejection, as shown by significantly
improved lung graft oxygenation and reduced rejection
scores. Gene therapy with recombinant adenoviral vectors is
currently being used in many clinical gene-transfer trials for
lung diseases, such as cystic fibrosis and lung cancer.13,14 In
experimental lung transplantation our laboratory has dem-
onstrated the beneficial effects of gene transfer with adeno-
virus vectors on ischemia-reperfusion injury and acute re-
jection in a rat lung graft model.4,10,15
However, most disease processes involve a combination
of different gene products. This might be a significant issue
for the future use of gene therapy because most current gene
therapy protocols only transfect one gene. Acute rejection is
a process of vascular and parenchymal injury mediated by T
cells, macrophages, and antibodies. The activated T cells
cause direct lysis of graft cells and produce cytokines that
recruit and activate inflammatory cells, which cause necro-
sis. Type 1 T-regulatory cells produce high levels of IL-10
and TGF-, and these cytokines mediate their ability to
suppress pathologic immune responses in the setting of
transplantation.16
Currently, drug-induced immunosuppression is the major
modality for preventing allograft rejection in the clinical
transplantation setting. Clinically used immunosuppressants
act in part by modulating the cytokine response of the
recipient immune system to the allograft. For example,
cyclosporine (INN: ciclosporin) inhibits the cytokine IL-2
and induces the synthesis of the immunosuppressive cyto-
kine TGF-1; similarly, FK506 also blocks the transcription
of IL-2.17,18 Thus, the prevention of allograft rejection re-
quires, in part, effective inhibition of IL-2 and induction of
immunosuppressive cytokines, such as TGF-1 and IL-10.
Immunosuppressants, however, have serious side effects,
especially when used for prolonged periods. Gene therapy
for lung transplantation, however, has the potential to in-
duce graft acceptance in the recipient without the use of
immunosuppressive drugs and their side effects.
In the present study cotransfection with TGF-1 and
IL-10 two days before transplantation suppressed IL-2 ex-
pression in lung grafts. TGF-1 transfection alone also
seemed to suppress IL-2 expression, showing that TGF-1,
rather than IL-10, might suppress IL-2. However, signifi-
cantly improved oxygenation and rejection scores resulting
from the synergistic effects of cotransfection with IL-10 and
TGF-1 suggest the existence of another unknown factor.
IL-10 belongs to the TH2 cytokine family, and the balance
between TH1 and TH2 cells in transplantation immunology
has been studied extensively. In most experimental allo-
transplantation models, rejection has generally been associ-
ated with high expression of TH1 cytokines (IL-2 and IFN-
), whereas TH2 cytokines (IL-10 and IL-4) have been
detected only slightly or not at all.19,20 The synergistic
930 The Journal of Thoracic and Cardiovascular Surgery ● Aprieffect of cotransfection with IL-10 and TGF-1 observed in
this study therefore might be related to an alteration in the
balance of the TH1 and TH2 cytokine responses to allograft
transplantation in the recipient.
In this study the TH1 cytokines IFN- and TNF- were
insufficiently not suppressed by TGF-1 and IL-10 overex-
pression. One of the potential reasons for this might be the
intramuscular transfection route used in this study. Our
group has recently shown that intratracheal administration
of adenoviral vector encoding the desired transgene is op-
timal in experimental lung transplantation in that it produces
the highest expression of the desired transgenic protein
within the lung graft itself.21 Although one advantage of
intramuscular transfection is that it avoids vector-induced
inflammation within the lung graft, the disadvantage is that
local concentrations of the desired transgenic protein within
the lung graft are lower than with intratracheal transfection.
We have also recently demonstrated that focal endobron-
chial transfection allows for the use of much less vector and
thus much less vector-induced inflammation.15 Thus future
work will examine whether endobronchial transfection can
effectively inhibit acute rejection and more potently sup-
press the production of proinflammatory cytokines. Another
reason that suppression of IFN- and TNF- could not be
demonstrated might be because levels of these cytokines
might peak during the early phase of the rejection process
rather than at the height of acute rejection, the time point
used for cytokine measurements in this study. Thus future
work will also further characterize early changes in the
process of graft rejection mediated by gene therapy with
immunosuppressive cytokines. Finally, future work will
also examine whether additional cotransfection with immu-
nosuppressive cytokines, which specifically inhibit the ac-
tion of IFN-, might create more effects on immunosup-
pression.
The timing of transfection is important in the clinical
setting. Transfection 2 days before transplantation is not
readily applicable to the clinical setting. The present study
showed that cotransfection at the time of harvest reduced
acute rejection. In light of the fact that only the cotrans-
fected group showed effects against rejection, the cotrans-
fection approach of recipient intramuscular injection of ad-
enoviral vector can be applied in the clinical setting.
However, IL-2, IFN-, and TNF- were not suppressed in
the group transfected at the time of harvest. This means that
TGF-1 and IL-10 expression might not be high enough in
the early phase of acute rejection. Our laboratory has shown
a synergistic benefit of cotransfection compared with trans-
fection of either cytokine alone.22,23 The advantage of co-
transfection is its synergistic effect, but its disadvantage is
that the inflammatory response might be increased because
of the increase in the quantity of adenovirus administered. It
might augment the formation of antibodies to the adenovi-
l 2005
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reduce the degree and duration of transgene expression.23
However, cotransfection might be required to regulate con-
current pathways in clinical gene therapy.
In conclusion, recipient intramuscular cotransfection of
TGF-1 and IL-10 suppressed IL-2 expression and pro-
vided a synergistic effect that reduced acute lung graft
rejection. The synergistic effects of multiple gene transfer
have great potential for reducing clinical acute lung graft
rejection.
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